• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai April 18 Wockhardt Ltd has formalised an in-licensing agreement with Advanced Biotechnologies Inc of US to market Kelocote, a patent-protected product to treat scars. Wockhardt plans to launch Kelocote in India in the third quarter of 2007.

Kelocote is a silicone gel to treat scars arising from accidents, burns, surgery and acne as well as skin disorders such as dermatitis and varicella, a Wockhardt note said.

In-licensing Deal

While clinical trials on Indian patients are in progress, clinical data from various countries has already proven its efficacy and cost-effectiveness, the note added. Kelocote is currently marketed in North America, Europe, Australia and South-East Asia. More than 100 million people acquire new scars each year in developed countries. Abnormal scars can be aesthetically distressing, disfiguring as well as psychologically disabling, the note said.

Last year, Wockhardt entered into an in-licensing deal with LSI of UK for Vitix, a patented product for vitiligo (leucoderma) and with Crawford Healthcare of UK for Viticolor, a camouflage gel for vitiligo-affected skins.

More Stories on : Outlook | Pharmaceuticals | New Products & Services

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
E&Y unveils outbound tax advisory service

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line